Literature DB >> 23730950

Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management.

Jose V Fernandez-Montero1, Eugenia Eugenia, Pablo Barreiro, Pablo Labarga, Vicente Soriano.   

Abstract

INTRODUCTION: The number of HIV patients receiving antiretroviral therapy is increasing worldwide, as new infections continue to occur and access to drugs is scaling up in most developing regions. Due to the efficacious nature of combination antiretroviral therapy in most drug-adherent patients, the concerns on the safety profile of these lifelong medicines have attracted great attention. AREAS COVERED: Side effects of antiretroviral agents can be clinically symptomatic or manifest only as laboratory abnormalities. Drug-related toxicities can be grouped by antiretroviral drug class or damage of distinct body organs/systems. By mechanism, antiretroviral-associated adverse events generally result from hypersensitivity reactions, direct cytopathic effect, or idiosyncratic phenomena. EXPERT OPINION: A good knowledge of the toxicity profile of antiretroviral agents is warranted for HIV care providers in order to prevent and avoid unwanted complications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23730950     DOI: 10.1517/14740338.2013.806480

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  8 in total

1.  Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.

Authors:  Li Liu; Bhavik Patel; Mustafa H Ghanem; Virgilio Bundoc; Zhili Zheng; Richard A Morgan; Steven A Rosenberg; Barna Dey; Edward A Berger
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

Review 2.  Chimeric antigen receptor engineered stem cells: a novel HIV therapy.

Authors:  Anjie Zhen; Mayra A Carrillo; Scott G Kitchen
Journal:  Immunotherapy       Date:  2017-03       Impact factor: 4.196

3.  Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada.

Authors:  H Samji; T E Taha; D Moore; A N Burchell; A Cescon; C Cooper; J M Raboud; M B Klein; M R Loutfy; N Machouf; C M Tsoukas; J S G Montaner; R S Hogg
Journal:  HIV Med       Date:  2014-09-01       Impact factor: 3.180

4.  Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus.

Authors:  Lauren Greenberg; Lene Ryom; Bastian Neesgaard; Gilles Wandeler; Therese Staub; Martin Gisinger; Michael Skoll; Huldrych F Günthard; Alexandra Scherrer; Cristina Mussini; Colette Smith; Margaret Johnson; Stéphane De Wit; Coca Necsoi; Christian Pradier; Ferdinand Wit; Clara Lehmann; Antonella d'Arminio Monforte; Jose M Miró; Antonella Castagna; Vincenzo Spagnuolo; Anders Sönnerborg; Matthew Law; Jolie Hutchinson; Nikoloz Chkhartishvili; Natalia Bolokadze; Jan-Christian Wasmuth; Christoph Stephan; Vani Vannappagari; Felipe Rogatto; Josep M Llibre; Claudine Duvivier; Jennifer Hoy; Mark Bloch; Heiner C Bucher; Alexandra Calmy; Alain Volny Anne; Annegret Pelchen-Matthews; Jens D Lundgren; Lars Peters; Loveleen Bansi-Matharu; Amanda Mocroft
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 20.999

5.  Indinavir and atazanavir; comparison of predicted property by chemoinformatics technique and implication on renal problem in HIV infected patients.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  J Nephropharmacol       Date:  2016-01-21

6.  CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection.

Authors:  Mary S Pampusch; Hadia M Abdelaal; Emily K Cartwright; Jhomary S Molden; Brianna C Davey; Jordan D Sauve; Emily N Sevcik; Aaron K Rendahl; Eva G Rakasz; Elizabeth Connick; Edward A Berger; Pamela J Skinner
Journal:  PLoS Pathog       Date:  2022-02-07       Impact factor: 6.823

7.  Rapid screening of HIV reverse transcriptase and integrase inhibitors.

Authors:  Steven J Smith; Stephen H Hughes
Journal:  J Vis Exp       Date:  2014-04-09       Impact factor: 1.355

8.  Targeted Spontaneous Reporting: Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale.

Authors:  Beth Rachlis; Rakhi Karwa; Celia Chema; Sonak Pastakia; Sten Olsson; Kara Wools-Kaloustian; Beatrice Jakait; Mercy Maina; Marcel Yotebieng; Nagalingeswaran Kumarasamy; Aimee Freeman; Nathalie de Rekeneire; Stephany N Duda; Mary-Ann Davies; Paula Braitstein
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.